Iambic Therapeutics is a California-based biotech leveraging its generative AI-driven discovery platform for protein-ligand complex structure prediction, enabling the design and development of novel chemistry against challenging biological targets. Iambic’s lead programs include a brain-penetrant HER2 TKI and a selective dual inhibitor of CDK 2/4. The technology was developed from the work of 2018 Nobel Prize winning chemist Francis Arnold from Caltech.